Institute of Graduate Studies in Health Sciences, Istanbul University, Istanbul, Turkey.
Faculty of Pharmacy, Yeditepe University, Istanbul, Turkey.
J Microencapsul. 2022 Jun;39(4):327-340. doi: 10.1080/02652048.2022.2079744. Epub 2022 Jun 1.
Loteprednol etabonate (LE) is a new generation corticosteroid that is used for the treatment of inflammatory and allergic conditions of the eye. Therefore, solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) were attempted to improve transdermal LE delivery for the first time.
SLN and NLC were produced by hot homogenisation and ultrasonication technique. Their physical stability was monitored for 3 months of storage. Drug release and permeation of SLN and NLC through the porcine skin were investigated.
It was determined that SLN and NLC mean particle size of 139.1 nm had a homogeneous particle size distribution (∼0.169 PI) and the mean charge was -23.6. They were found to be stable both physically and chemically at room temperature.
SLN and NLC formulations of LE can be stated among the systems that can be an alternative to conventional systems with fewer side-effects in the treatment of inflammatory problems.
依托泊苷酯（LE）是一种新型皮质类固醇，用于治疗眼部的炎症和过敏疾病。因此，首次尝试使用固体脂质纳米粒（SLN）和纳米结构脂质载体（NLC）来改善 LE 的经皮给药。
通过热匀化和超声技术制备 SLN 和 NLC。在储存 3 个月期间监测其物理稳定性。研究了 SLN 和 NLC 通过猪皮的药物释放和渗透。
确定了粒径为 139.1nm 的 SLN 和 NLC 具有均匀的粒径分布（约 0.169PI）和平均电荷为-23.6。它们在室温下表现出良好的物理和化学稳定性。
LE 的 SLN 和 NLC 制剂可作为传统系统的替代方案，在治疗炎症问题时副作用更少。
